Cadila Healthcare slips 4.5% from day's high post June quarter results

The company's consolidated revenue grew 4 per cent on a yearly basis to Rs 3,639.9 crore, compared to Rs 3,496.3 crore reported in the June quarter of FY20
Shares of Cadila Healthcare slipped 2.4 per cent to Rs 392.85 on the BSE on Wednesday after the company reported flat operational performance in April-June quarter of FY20. The stock of the pharmaceutical firm declined 4.5 per cent from its intra-day high of Rs 411.60, also its 52-week high, touched earlier in the day.

The company's consolidated revenue grew 4 per cent on a yearly basis to Rs 3,639.9 crore, compared to Rs 3,496.3 crore reported in the June quarter of FY20. Sequentially, the revenue from operations dipped 3 per cent from Rs 3,752.1 crore logged in Q4FY20.

The company's India business which comprises human formulations, consumer wellness and animal health business posted sales amounting to Rs 1,486 crore during the quarter.

It's net profit, however, came in at Rs 454 crore, clocking a 49.53 per cent growth YoY from Rs 303.6 crore reported in Q1FY20. In the March quarter of FY20, the profit was Rs 391.9 crore. Profit before tax (PBT), too, soared 50.64 per cent to Rs 593.40 crore in Q1FY20 as against Rs 393.90 crore in Q1FY19. Current tax expense for the quarter jumped 106.39 per cent at Rs 106.50 crore as against Rs 51.60 crore in Q1 June 2019. 

EBIDTA for the quarter stood at Rs 815 crore. EBIDTA margin was at 22.4 per cent, registering an improvement of 360 basis points over the corresponding quarter of the previous financial year. 

Meanwhile, in a separate announced on Wednesday, the company announced that its plasmid DNA vaccine to prevent Covid-19, ZyCoV-D was found to be safe and well tolerated in the Phase-I clinical trial. The company will now commence Phase II clinical trials from the 6 August 2020, it said. READ REGULATORY FILING HERE

Continuing with its efforts to look at new therapeutic options to manage and treat the Covid-19, Zydus received approvals from COFEPRIS of Mexico for clinical trials of Pegylated Interferon Alpha 2b in Covid-19 patients. At present, clinical trials in India and Mexico are underway with Pegylated Interferon alpha-2b. That apart, the pharmaceutical major has also received an approval to conduct clinical trials with Desidustat, its Investigational New Drug, for the management of Covid-19 patients in Mexico from COFEPRIS. The firm announced the commencement of the Adaptive Phase I/II clinical trials of ZYCoV-D, the preventive vaccine for Covid-19 in India.

At 1:57 pm, the stock was down 1.5 per cent at Rs 398 per share, as against 53 points, or 0.14 per cent, decline in the S&P BSE Sensex.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel